News Release

Global biotech firm partners with CHEO researcher to address a technology gap in infectious disease

Dr. Robert Slinger recognized as expert in field of infectious disease

Business Announcement

Children's Hospital of Eastern Ontario Research Institute

OTTAWA, ON – October 3, 2011 – The Children's Hospital of Eastern Ontario (CHEO) Research Institute is pleased to announce that one of its principal investigators in infectious disease has signed a contract with Life Technologies, an internationally renowned biotech tools company headquartered in Carlsbad, California, to share information that will help to develop tests that uniquely amplify and detect the DNA coding for infectious diseases. Dr. Robert Slinger will focus on bacteria that cause severe infectious diseases.

"I believe Life Technologies to be a leader in its field, so it was an honor to be approached about contributing to this project," said Dr. Slinger, a CHEO Medical Microbiologist and Pediatric Infectious Diseases physician. "Life Technologies is one of the only companies in the world that has the full suite of technology to look at detection of infectious disease agents from extracting DNA and RNA from a sample to amplifying and detecting the results. I think they're ahead of the curve yet again, by bringing microbial testing to their innovation roadmap."

Dr. Slinger and Life Technologies are partnering with the objective to co-develop microbial detection tests. In short, they will identify the unique DNA sequence of targeted infectious disease pathogens which will ultimately be used to create tests that will rapidly and clearly indicate when a targeted infectious agent has been identified in a patient sample. Samples will be tested with "all-inclusive" panels that include tests for large numbers (e.g. 30-50) of infectious agents. This approach will ensure that all possible causes of the patient's infection are looked for at the same time, which Dr. Slinger believes will ultimately lead to better antibiotic treatment for patients.

"Dr. Slinger is well known as one of the first to use molecular panel technology to test for infectious disease in humans," said Astrid Ferlinz, Life Technologies' Global Market Development Manager, Darmstadt, Germany. "We're now embarking on a strategic partnership with Dr. Slinger that will one day alter how we look for infectious disease to help patients; but also to protect the public from contracting serious infections that can't be detected by current lab methods (for instance, consider the E. coli outbreak in Germany this spring)."

###

About Dr. Slinger:

Dr. Robert Slinger is an Associate Professor in the Departments of Laboratory Medicine and Pediatrics at the University of Ottawa. He works as Medical Microbiologist and Pediatric Infectious Diseases physician at CHEO, and is the Director for the Medical Microbiology residency program. He obtained his medical degree at Queens University in Kingston, ON, his certification in both Pediatrics and in Medical Microbiology at the University of Ottawa, and his Infectious Disease certification at the University of Manitoba in Winnipeg. His research focus is the rapid molecular detection and identification of infectious disease agents.

About the CHEO Research Institute:

Established in 1984, the CHEO Research Institute coordinates the research activities of the Children's Hospital of Eastern Ontario (CHEO) and is one of the institutes associated with the University of Ottawa Teaching Hospitals. The Research Institute brings together health professionals from within CHEO to share their efforts in solving paediatric health problems. It also promotes collaborative research outside the hospital with partners from the immediate community, industry and the international scientific world. For more information, visit www.cheori.org


Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.